
SyntheticGestalt (Shinjuku, Tokyo; CEO Koki Shimada; hereinafter "our company") is pleased to announce its participation in BIO International Convention 2025 to be held in Boston in June, with support from the Japan External Trade Organization (JETRO).
Our company will showcase its innovative foundation AI model (SG4D10B) trained on 10 billion compound data points. This model achieves analysis and prediction accuracy that significantly surpass conventional molecular AI technologies. We currently have a limited number of individual consultation slots available for North American companies seeking AI solutions in pharmaceuticals, food, and chemical development.
Our company's participation in the BIO International Convention marks a strategic step toward expansion into the North American market. We have built a solid track record through collaborations with major domestic pharmaceutical, food, and materials manufacturers in Japan, and have been selected for multiple government innovation support programs.
Our AI system is distinguished by its extensive compound database, specialized algorithms, and proven results in R&D process efficiency. Through collaborations with industry leaders, we have achieved concrete results in compound research and development. These initiatives have resulted in significant reductions in development time and research costs, with some projects demonstrating efficiency improvements of over 30% compared to conventional methods. In our collaboration with Enamine, we successfully narrowed down 38 billion library compounds to 40 promising compounds. What would typically cost £800,000 and take 12 months using conventional methods was achieved for just £80,000 in 3 months, representing a 90% cost reduction and 75% time reduction.
Our individual consultation slots at BIO International Convention are limited to 10 companies specifically for potential new partners in the North American market. Daisuke Morohashi, Head of AI Business, states: "We plan to advance PoC (Proof of Concept) and joint development projects with three U.S. companies this year. We will prioritize partnerships with companies that have clear needs for development streamlining and efficiency improvements, and demonstrate strong compatibility with our platform. Since individual consultation slots during BIO International Convention are limited to 10 companies, we look forward to reservations from interested companies."
At our booth, we will conduct demonstrations and provide opportunities for individual consultations with our technical and business development teams. We encourage interested companies to make reservations.
Contact: Daisuke Morohashi (d.morohashi@syntheticgestalt.com)
About SyntheticGestalt
SyntheticGestalt develops AI technology specialized in molecular information. In 2024 and 2025, we unveiled the world's largest molecule-specific foundation model at NVIDIA GTC. Our molecular foundation model resolves accuracy challenges faced by conventional molecular AI. We aim to apply this technology across various fields including pharmaceuticals, cosmetics, agrochemicals, and new materials. Our mission is to contribute to the advancement of civilization through AI-driven innovations.
